About
About Kingworld Medicines Group Limited
Kingworld Medicines Group Limited, an investment holding company, primarily engages in the distribution, manufacture, and sale of branded imported pharmaceutical and healthcare products. The company offers products for relieving cough, alleviating phlegm, soothing asthma, enhancing respiratory system, aiding digestion, promoting intestinal health, activating blood circulation, relieving pain, combating flu, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, and Kingworld Imada Red Flower Oil brands. It also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices; and supplies pharmaceuticals, healthcare, general foodstuffs, and medical products. In addition, the company is involved in the distribution and sale of artwork; organization of art exhibitions; distribution and sale of Chinese medicine; and engages in technology transfer and property investment activities. It operates in the People's Republic of China, France, the United States, Hong Kong, the United Kingdom, Germany, Italy, Spain, Mexico, and internationally. The company was founded in 1996 and is headquartered in Shenzhen, the People's Republic of China.
Visit company website
5 years, 4 months ago
Kingworld Medicines Group Limited is currently in a long term downtrend where the price is trading 1.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Kingworld Medicines Group Limited's total revenue sank by 36.2% to $293M since the same quarter in the previous year.
Its net income has dropped by 6.6% to $10M since the same quarter in the previous year.
Finally, its free cash flow fell by 26.0% to $16M since the same quarter in the previous year.
Based on the above factors, Kingworld Medicines Group Limited gets an overall score of 1/5.